Regarding the rationale for continuation of trastuzumab monotherapy, the ToGA (as shown in Fig. 3) and HERA trials demonstrated that continuous treatment with a single agent was capable of inhibiting HER2-positive tumor growth. Here, ERBB2 is linked to neoplasm.